Cellectis S.A, University of Texas MD Anderson Cancer Center deal

MD Anderson and Cellectis partnered to co-develop four allogeneic chimeric antigen receptor T cell therapies from Cellectis to treat non-solid tumors. Cellectis’ candidates are expected to enter clini...